Head-to-head
Ro vs Hims & Hers
The two largest GLP-1 telehealth brands. They sit at opposite ends of the formulary-vs-cost trade-off — Ro carries every FDA-approved GLP-1 and handles insurance PA; Hims wins on price with the $149/mo oral Wegovy starter but a narrower drug list.
Side-by-side
| Axis | Ro | Hims & Hers |
|---|---|---|
| Starting monthly price (cash) | $349/mo (injectable Wegovy) | $149/mo (oral Wegovy starter) |
| Drug selection | All FDA-approved GLP-1s (Wegovy, Zepbound, Ozempic, Mounjaro, Foundayo) | Oral Wegovy, injectable Wegovy, compounded semaglutide |
| Insurance handling | Full PA submission, 48-hour turnaround | Cash-pay only |
| App + UX polish | Native iOS/Android, message-thread workflow | Web-first, lighter app |
| Coaching | Optional, paid add-on | Not included |
- Starting monthly price (cash): Hims is roughly 57% cheaper for the first 3-4 months while titrating.
- Drug selection: If your prescriber lands on Zepbound or Foundayo, Hims cannot fulfill.
- Insurance handling: Ro has reported ~71% first-pass PA approval rate (editorially audited Q1 2026).
- App + UX polish: Both are above the telehealth average.
- Coaching: Neither is the right pick if coaching is your primary value — see Sequence or Calibrate.
Bottom line
Pick Ro if
You have commercial insurance and want to use it, OR you specifically want Zepbound / Mounjaro / Foundayo (Hims does not carry these).
See Ro reviewPick Hims & Hers if
You're cash-pay, want to start at the lowest possible monthly price, and oral semaglutide fits your use case.
See Hims & Hers reviewAffiliate links. Glpverdict may earn a commission when you sign up. Our editorial ranking is independent — see how we rank.
Other head-to-head comparisons